BioNTech and CEPI partnership to advance mRNA Mpox Vaccine development
The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases
The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases
The complexity of operating on a one-year-old are many with the organs being tiny, fragile
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
The inspection has concluded successfully on 1st September 2023 without any critical/major observation
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
Subscribe To Our Newsletter & Stay Updated